These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38758189)

  • 1. Global epidemiology and antimicrobial resistance of Enterobacterales harbouring genes encoding OXA-48-like carbapenemases: insights from the results of the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme 2018-2021.
    Lee YL; Wang WY; Ko WC; Hsueh PR
    J Antimicrob Chemother; 2024 Jul; 79(7):1581-1589. PubMed ID: 38758189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic and molecular characterization of multidrug-resistant Enterobacterales isolated from clinical samples in Palestine: a focus on extended-spectrum β-lactamase- and carbapenemase-producing isolates.
    Ibaideya MA; Taha AA; Qadi M
    BMC Infect Dis; 2024 Aug; 24(1):812. PubMed ID: 39134953
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Stone G; Wise M; Utt E
    Microbiol Spectr; 2024 Mar; 12(3):e0147323. PubMed ID: 38329363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ceftazidime/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli.
    Öztaş S; Er DK; Dündar D; Keçeli SA
    Acta Microbiol Immunol Hung; 2024 Jul; 71(2):110-120. PubMed ID: 38837219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
    Piérard D; Stone GG
    BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
    Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of carbapenem-resistant
    Yan WJ; Jing N; Wang SM; Xu JH; Yuan YH; Zhang Q; Li AL; Chen LH; Zhang JF; Ma B; Ma Q; Li Y
    J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33587030
    [No Abstract]   [Full Text] [Related]  

  • 9. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020.
    Lee YL; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2022; 60(5-6):106679. PubMed ID: 36241011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characteristics of carbapenemase-producing Enterobacterales in the Netherlands; results of the 2014-2018 national laboratory surveillance.
    van der Zwaluw K; Witteveen S; Wielders L; van Santen M; Landman F; de Haan A; Schouls LM; Bosch T;
    Clin Microbiol Infect; 2020 Oct; 26(10):1412.e7-1412.e12. PubMed ID: 32006688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and antimicrobial susceptibility profiles of Enterobacterales causing bloodstream infections before and during COVID-19 pandemic: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2018-2021.
    Lee YL; Liu CE; Tang HJ; Huang YT; Chen YS; Hsueh PR;
    J Microbiol Immunol Infect; 2024 Jun; 57(3):446-456. PubMed ID: 38632023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
    Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
    Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae from Bangkok, Thailand, and Their Detection by the Carba NP and Modified Carbapenem Inactivation Method Tests.
    Laolerd W; Akeda Y; Preeyanon L; Ratthawongjirakul P; Santanirand P
    Microb Drug Resist; 2018 Sep; 24(7):1006-1011. PubMed ID: 29782216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enterobacterales carrying chromosomal AmpC β-lactamases in Europe (EuESCPM): Epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020-2022.
    Boattini M; Bianco G; Llorente LI; Acero LA; Nunes D; Seruca M; Mendes VS; Almeida A; Bastos P; Rodríguez-Villodres Á; Gascón AG; Halperin AV; Cantón R; Escartín MNL; González-López JJ; Floch P; Massip C; Chainier D; Barraud O; Dortet L; Cuzon G; Zancanaro C; Mizrahi A; Schade R; Rasmussen AN; Schønning K; Hamprecht A; Schaffarczyk L; Glöckner S; Rödel J; Kristóf K; Balonyi Á; Mancini S; Quiblier C; Fasciana T; Giammanco A; Paglietti B; Rubino S; Budimir A; Bedenić B; Rubic Z; Marinović J; Gartzonika K; Christaki E; Mavromanolaki VE; Maraki S; Yalçın TY; Azap ÖK; Licker M; Musuroi C; Talapan D; Vrancianu CO; Comini S; Zalas-Więcek P; Michalska A; Cavallo R; Melo Cristino J; Costa C
    Int J Antimicrob Agents; 2024 May; 63(5):107115. PubMed ID: 38367844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of multidrug-resistant Enterobacteriaceae in Sri Lanka: First evidence of bla
    Kumudunie WGM; Wijesooriya LI; Namalie KD; Sunil-Chandra NP; Wijayasinghe YS
    J Infect Public Health; 2020 Sep; 13(9):1330-1335. PubMed ID: 32439355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.
    García-Castillo M; García-Fernández S; Gómez-Gil R; Pitart C; Oviaño M; Gracia-Ahufinger I; Díaz-Regañón J; Tato M; Cantón R;
    Int J Antimicrob Agents; 2018 Mar; 51(3):511-515. PubMed ID: 29371104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic and Genotypic Characterization of Carbapenem-resistant Enterobacteriaceae: Data From a Longitudinal Large-scale CRE Study in China (2012-2016).
    Wang Q; Wang X; Wang J; Ouyang P; Jin C; Wang R; Zhang Y; Jin L; Chen H; Wang Z; Zhang F; Cao B; Xie L; Liao K; Gu B; Yang C; Liu Z; Ma X; Jin L; Zhang X; Man S; Li W; Pei F; Xu X; Jin Y; Ji P; Wang H
    Clin Infect Dis; 2018 Nov; 67(suppl_2):S196-S205. PubMed ID: 30423057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of β-lactamases and emergence of carbapenemases co-occurring Enterobacterales isolates with high-level antibiotic resistance identified from patients with intra-abdominal infection in the Asia-Pacific region, 2015-2018.
    Chen YC; Chen WY; Hsu WY; Tang HJ; Chou Y; Chang YH; Chen CC; Chuang YC; Chang TH
    J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 2):1263-1272. PubMed ID: 34330663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emergence of carbapenemase bla
    Tawfick MM; Alshareef WA; Bendary HA; Elmahalawy H; Abdulall AK
    Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1251-1259. PubMed ID: 32062725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early OXA-48-Producing
    Gijón D; Tedim AP; Valverde A; Rodríguez I; Morosini MI; Coque TM; Manrique M; Pareja E; Tobes R; Ruiz-Garbajosa P; Cantón R
    mSphere; 2020 Apr; 5(2):. PubMed ID: 32269151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.